| Dr James D Lakin, MD, PHD, MBA | |
|
350 W Burnsville Pkwy, Suite 200, Burnsville, MN 55337-2585 | |
| (952) 223-3050 | |
| Not Available |
| Full Name | Dr James D Lakin |
|---|---|
| Gender | Male |
| Speciality | Allergy & Immunology |
| Location | 350 W Burnsville Pkwy, Burnsville, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417027822 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 33295 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr James D Lakin, MD, PHD, MBA 350 W Burnsville Pkwy, Suite 200, Burnsville, MN 55337-2585 Ph: (952) 223-3050 | Dr James D Lakin, MD, PHD, MBA 350 W Burnsville Pkwy, Suite 200, Burnsville, MN 55337-2585 Ph: (952) 223-3050 |
News Archive
Biofield Corp. announced today that its 51% owned subsidiary, Sky Unicorn Holdings Ltd., has engaged McKinley Infocapital as its exclusive distributor in Korea for its flagship product, the Biofield Breast Diagnostic System (BDS). McKinley Infocapital, an international business consulting and investment management firm, has formed MacKay Life Sciences Korea to market and promote the BDS in Korea.
Over and over again, President Obama has promised not to raise "any form" of taxes on families making less than $250,000 per year. Yet, the U.S. Senate is getting ready to consider a government healthcare bill which does just that.
Rape is shockingly common in the slums of Nairobi, Kenya, where as many as one in four adolescent girls are raped each year. But a short self-defense course can dramatically reduce the girls' vulnerability to sexual assault, according to a new study from the Stanford University School of Medicine, Lucile Packard Children's Hospital and an organization called No Means No Worldwide.
Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.
A new preprint research paper posted to the bioRxiv* server describes the results of a nuclear magnetic resonance (NMR) study to determine the structure of the S protein transmembrane domain (TMD) and its membrane-proximal regions.
› Verified 9 days ago
Dr. Andrew Nickels, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 14000 Fairview Dr, Burnsville, MN 55337 Phone: 952-993-8700 |